Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 3
1993 4
1994 4
1995 5
1996 7
1997 5
1998 8
1999 4
2000 7
2001 2
2002 2
2003 4
2004 3
2005 5
2006 4
2007 2
2008 6
2009 2
2010 6
2011 3
2012 4
2013 4
2014 3
2015 4
2016 1
2017 3
2019 1
2021 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Zopolrestat Induced Suicidal Death of Human Erythrocytes.
Bouguerra G, Bissinger R, Abbès S, Lang F. Bouguerra G, et al. Cell Physiol Biochem. 2015;37(4):1537-46. doi: 10.1159/000438521. Epub 2015 Oct 30. Cell Physiol Biochem. 2015. PMID: 26512879 Free article.
BACKGROUND/AIMS: The aldose reductase inhibitor zopolrestat has been shown to either decrease or increase apoptosis, the suicidal death of nucleated cells. ...The effect of zopolrestat on annexin-V-binding was significantly blunted, but not abolished by removal of e …
BACKGROUND/AIMS: The aldose reductase inhibitor zopolrestat has been shown to either decrease or increase apoptosis, the suicidal dea …
Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
Wilson DK, Tarle I, Petrash JM, Quiocho FA. Wilson DK, et al. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9847-51. doi: 10.1073/pnas.90.21.9847. Proc Natl Acad Sci U S A. 1993. PMID: 8234324 Free PMC article.
We report the refined 1.8 A x-ray structure of the human holoenzyme complexed with zopolrestat, one of the most potent noncompetitive inhibitors. The zopolrestat fits snugly in the hydrophobic active site pocket and induces a hinge-flap motion of two peptide segment …
We report the refined 1.8 A x-ray structure of the human holoenzyme complexed with zopolrestat, one of the most potent noncompetitive …
Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury.
Tracey WR, Magee WP, Ellery CA, MacAndrew JT, Smith AH, Knight DR, Oates PJ. Tracey WR, et al. Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1447-52. doi: 10.1152/ajpheart.2000.279.4.H1447. Am J Physiol Heart Circ Physiol. 2000. PMID: 11009428 Free article.
Zopolrestat reduced myocardial sorbitol concentration (index of AR activity) by >50% (control, 15.0 +/- 2.2 nmol/g; 200 nM zopolrestat, 6.7 +/- 1.3 nmol/g). A modestly cardioprotective concentration of CB-MECA (0.2 nM) allowed a 50-fold reduction in zopolresta
Zopolrestat reduced myocardial sorbitol concentration (index of AR activity) by >50% (control, 15.0 +/- 2.2 nmol/g; 200 nM zopo
Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T, Petrash JM. Nakano T, et al. Biochemistry. 1996 Aug 27;35(34):11196-202. doi: 10.1021/bi9608121. Biochemistry. 1996. PMID: 8780524
The present study was undertaken to address this apparent discrepancy. Using a fluorometric assay, it was determined that zopolrestat, an acetic acid-type inhibitor, bound to aldose reductase complexed with either NADPH or NADP+. In contrast, the spirohydantoin-type inhibi …
The present study was undertaken to address this apparent discrepancy. Using a fluorometric assay, it was determined that zopolrestat
Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury.
Ramasamy R, Oates PJ, Schaefer S. Ramasamy R, et al. Diabetes. 1997 Feb;46(2):292-300. doi: 10.2337/diab.46.2.292. Diabetes. 1997. PMID: 9000707
Zopolrestat reduced sorbitol levels before ischemia in diabetic hearts. ...Zopolrestat provided similar metabolic and functional benefits in nondiabetic hearts. ...
Zopolrestat reduced sorbitol levels before ischemia in diabetic hearts. ...Zopolrestat provided similar metabolic and function
Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
Mylari BL, Larson ER, Beyer TA, Zembrowski WJ, Aldinger CE, Dee MF, Siegel TW, Singleton DH. Mylari BL, et al. J Med Chem. 1991 Jan;34(1):108-22. doi: 10.1021/jm00105a018. J Med Chem. 1991. PMID: 1899452
Optimization of this lead through medicinal chemical rationale, including analogy from other drug series, led to more potent congeners of 207 and culminated in the design of 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (216, CP-73,8 …
Optimization of this lead through medicinal chemical rationale, including analogy from other drug series, led to more potent congeners of 20 …
Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
Beyer-Mears A, Diecke FP, Mistry K, Cruz E. Beyer-Mears A, et al. Pharmacology. 1997 Feb;54(2):76-83. doi: 10.1159/000139472. Pharmacology. 1997. PMID: 9088040
The effects of two structurally dissimilar aldose reductase inhibitors, Zopolrestat and Sorbinil, were investigated on the sodium-dependent, myo-inositol (MI) cotransporter in rat lenses maintained in either normal (5.5 mmol/l) or high sugar medium (35.5 mmol/l glucose or …
The effects of two structurally dissimilar aldose reductase inhibitors, Zopolrestat and Sorbinil, were investigated on the sodium-dep …
Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus.
Beyer-Mears A, Mistry K, Diecke FP, Cruz E. Beyer-Mears A, et al. Pharmacology. 1996 May;52(5):292-302. doi: 10.1159/000139394. Pharmacology. 1996. PMID: 8807673
The aldose reductase inhibitor, Zopolrestat, reduced proteinuria and albuminuria in streptozocin-induced diabetic rats compared with both untreated diabetic and age-matched controls. ...Zopolrestat protected against excretion of any array of urinary proteins with mo …
The aldose reductase inhibitor, Zopolrestat, reduced proteinuria and albuminuria in streptozocin-induced diabetic rats compared with …
Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat.
Ramasamy R, Liu H, Oates PJ, Schaefer S. Ramasamy R, et al. Cardiovasc Res. 1999 Apr;42(1):130-9. doi: 10.1016/s0008-6363(98)00303-4. Cardiovasc Res. 1999. PMID: 10435004
To further explore potential cardioprotective mechanisms of zopolrestat, we measured changes in intracellular sodium, calcium, and Na+,K(+)-ATPase activity in zopolrestat treated hearts during ischemia and reperfusion. ...The end-ischemic [Na]i was 21.3 +/- 2.6 mM i …
To further explore potential cardioprotective mechanisms of zopolrestat, we measured changes in intracellular sodium, calcium, and Na …
Bioavailability, multiple-dose pharmacokinetics, and biotransformation of the aldose reductase inhibitor zopolrestat in dogs.
Schneider RP, Davenport CJ, Hoffmaster KA, Inskeep PB. Schneider RP, et al. Drug Metab Dispos. 1998 Nov;26(11):1160-6. Drug Metab Dispos. 1998. PMID: 9806960
Zopolrestat (Alond) is a new drug that is being evaluated as an aldose reductase inhibitor for the treatment of diabetic complications. ...The magnitude of the potential gender difference in exposure was relatively small and was unlikely to have had a meaningful impact on
Zopolrestat (Alond) is a new drug that is being evaluated as an aldose reductase inhibitor for the treatment of diabetic complication
107 results